Siemens Healthineers and National University Hospital Partner on Research to Advance Non-Invasive Liver Disease Diagnostics
Partnership will evaluate advanced ultrasound technologies to improve early detection and monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease Advancing ultrasound technologies that are safer, more accessible alternatives to invasive diagnostic procedures Research led by globally respected hepatologist Associate Professor Dan Yock Young SINGAPORE, Oct. 8, 2025 /PRNewswire/ --...
Hope Medicine Inc. Announces Successful Completion of a Global Phase 2 Study of a Potential First-in-Class Endometriosis Treatment
HMI-115 demonstrated statistically significant improvement in endometriosis pain The mean dysmenorrhea pain score was reduced by 42% The mean non-menstrual pelvic pain score was reduced by 52% Most of the patients had normal menstrual periods No typical peri-menopausal symptoms were reported There were no significant changes in bone mineral density and sex hormone levels About 190 million women...
New White Paper by APAC CVD Alliance and Deloitte Charts Path to Tackle Rising Heart Failure Burden in Asia-Pacific
32 million people in Asia-Pacific live with heart failure, and this number is rising fast. New blueprint targets a 20% cut in hospitalisations and 15% boost in survival rates within 5 years. Urgent call for early diagnosis, digital and community-based care, and sustainable financing to save lives and reduce costs. ...
CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
SHANGHAI, Oct. 8, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of CT071 (an autologous CAR T-cell product targeting GPRC5D) for the treatment of relapsed/refractory multiple myeloma (R/R MM) in an investigator-initiated trial (NCT05838131) have been published...
New Global Beauty & Wellbeing Report unveils Emotional Wellbeing as the True Face of Beauty
New proprietary research from Oriflame redefines beauty as a powerful driver of wellbeing STOCKHOLM, Oct. 8, 2025 /PRNewswire/ -- Global beauty and wellbeing company, Oriflame, today releases its first Beauty & Wellbeing Report, revealing a major shift in how women around the world experience and define beauty. Based on a study of 3,500 women across seven countries, the report highlights...
Global Direct Selling Leader QNET Celebrates 27 Years, Showcasing Economic Impact and Announces Landmark Ghana Convention
PENANG, Malaysia, Oct. 8, 2025 /PRNewswire/ -- QNET, a leading global lifestyle and wellness direct selling company, concluded its spectacular 27th-anniversary convention, V-Malaysia 2025, in Penang this week. The event, endorsed by Tourism Malaysia, welcomed over 10,000 independent distributors from more than 30 countries, serving as a powerful testament to the company's global community and the significant economic benefits...
Cyteph Completes Recruitment for Phase I Clinical Trial of CYT-101 in Patients with Recurrent Glioblastoma Multiforme Brain Cancer
BRISBANE, Australia, Oct. 8, 2025 /PRNewswire/ -- Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully completed recruitment for its first-in-human Phase I clinical trial of CYT-101. CYT-101 is a novel off-the-shelf, HLA-matched CMV-specific T cell therapy for the treatment of glioblastoma multiforme (GBM) and other solid cancers. GBM is...
An Era Where Meditation Becomes a Quantifiable Achievement — Japan’s First “Quantified Meditation Challenge”
TOKYO, Oct. 7, 2025 /PRNewswire/ -- Meditation entered a new era as the World Meditation League (WML), and All Here introduced Japan's first Tokyo Quantified Meditation Challenge in the gardens of Happo-en. Tokyo Quantified Meditation Challenge organised by the World Meditation League and All Here This unprecedented event took...
Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing
TOKYO, Oct. 7, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid"), today announced the successful completion of the 1st Close of its Series B financing round, raising JPY 1.055 billion (USD 7.2 million) from venture capital firms and the Japan Agency for Medical Research and Development (AMED). Including grants and subsidies, Celaid's cumulative funding has reached JPY 2.52 billion...
ZEISS expands DORC portfolio and further strengthens digital footprint with improved workflow efficiency and digital visualization
Showcasing at AAO 2025: NEW 510k CLEARANCE SUPPORTS MORE INFORMED DECISION MAKING & PATHOLOGY DETECTION: Showcasing optical coherence tomography angiography (OCT-A) with ZEISS CIRRUS AngioPlex® with noninvasive imaging of the retinal and choroidal vasculature; now with 510k clearance and CE approval, ICGA for CLARUS® 700 offers FA + ICG simultaneous capture....
